Literature DB >> 18541549

Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial.

Jeremy D Furtado1, Hannia Campos, Lawrence J Appel, Edgar R Miller, Nancy Laranjo, Vincent J Carey, Frank M Sacks.   

Abstract

BACKGROUND: Plasma apolipoprotein B (apo B) and VLDL and LDL with apolipoprotein C-III (apo C-III) are independent risk factors for cardiovascular disease (CVD). Dietary intake affects lipoprotein concentration and composition related to those apolipoproteins.
OBJECTIVE: We studied differences in apo B lipoproteins with and without apo C-III after 3 healthy diets based on the Dietary Approaches to Stop Hypertension Trial diet.
DESIGN: Healthy participants (n = 162) were fed each of 3 healthy diets for 6 wk in a crossover design. Diets differed by emphasis of either carbohydrate (Carb), unsaturated fat (Unsat), or protein (Prot). Blood was collected at baseline and after diets for analysis.
RESULTS: Compared with the Carb diet, the Prot diet reduced plasma apo B and triglycerides in VLDL with apo C-III (16%, P = 0.07; 11%, P = 0.05, respectively) and apo B in LDL with apo C-III (16%, P = 0.04). Compared with the Unsat diet, the Prot diet reduced triglycerides in VLDL with apo C-III (16%, P = 0.02). Compared with baseline (subjects' usual diet was higher in saturated fat), the Prot diet reduced apo B in LDL with apo C-III (11%, P = 0.05), and all 3 diets reduced plasma total apo B (6-10%, P < 0.05) and apo B in the major type of LDL, LDL without apo C-III (8-10%, P < 0.01). All 3 diets reduced the ratio of apo C-III to apo E in VLDL.
CONCLUSIONS: Substituting protein for carbohydrate in the context of a healthy dietary pattern reduced atherogenic apo C-III-containing LDL and its precursor, apo C-III-containing VLDL, resulting in the most favorable profile of apo B lipoproteins. In addition, compared with a typical high-saturated fat diet, healthy diets that emphasize carbohydrate, protein, or unsaturated fat reduce plasma total and LDL apo B and produce a lower more metabolically favorable ratio of apo C-III to apo E.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541549      PMCID: PMC2494528          DOI: 10.1093/ajcn/87.6.1623

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  31 in total

1.  The effect on serum-cholesterol of diets containing different fats.

Authors:  H MALMROS; G WIGAND
Journal:  Lancet       Date:  1957-07-06       Impact factor: 79.321

2.  Serum cholesterol response to dietary cholesterol.

Authors:  A Keys
Journal:  Am J Clin Nutr       Date:  1984-08       Impact factor: 7.045

3.  Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial.

Authors:  E Obarzanek; F M Sacks; W M Vollmer; G A Bray; E R Miller; P H Lin; N M Karanja; M M Most-Windhauser; T J Moore; J F Swain; C W Bales; M A Proschan
Journal:  Am J Clin Nutr       Date:  2001-07       Impact factor: 7.045

4.  Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation.

Authors:  Akio Kawakami; Masanori Aikawa; Noriko Nitta; Masayuki Yoshida; Peter Libby; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-10-12       Impact factor: 8.311

5.  Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.

Authors:  Chunyu Zheng; Christina Khoo; Katsunori Ikewaki; Frank M Sacks
Journal:  J Lipid Res       Date:  2007-02-21       Impact factor: 5.922

6.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

7.  Risk factors for cardiovascular disease and diabetes in two groups of Hispanic Americans with differing dietary habits.

Authors:  H Alexander; L P Lockwood; M A Harris; C L Melby
Journal:  J Am Coll Nutr       Date:  1999-04       Impact factor: 3.169

8.  Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (OmniHeart): options for a heart-healthy diet.

Authors:  Janis F Swain; Phyllis B McCarron; Eileen F Hamilton; Frank M Sacks; Lawrence J Appel
Journal:  J Am Diet Assoc       Date:  2008-02

9.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Authors:  D H Blankenhorn; S A Nessim; R L Johnson; M E Sanmarco; S P Azen; L Cashin-Hemphill
Journal:  JAMA       Date:  1987-06-19       Impact factor: 56.272

10.  Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E.

Authors:  L Chivot; F Mainard; E Bigot; J M Bard; J L Auget; Y Madec; J C Fruchart
Journal:  Atherosclerosis       Date:  1990-06       Impact factor: 5.162

View more
  29 in total

Review 1.  The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?

Authors:  Arne Astrup; Jørn Dyerberg; Peter Elwood; Kjeld Hermansen; Frank B Hu; Marianne Uhre Jakobsen; Frans J Kok; Ronald M Krauss; Jean Michel Lecerf; Philippe LeGrand; Paul Nestel; Ulf Risérus; Tom Sanders; Andrew Sinclair; Steen Stender; Tine Tholstrup; Walter C Willett
Journal:  Am J Clin Nutr       Date:  2011-01-26       Impact factor: 7.045

2.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

Review 3.  Dietary monounsaturated fatty acids appear not to provide cardioprotection.

Authors:  Chiara Degirolamo; Lawrence L Rudel
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

4.  A modified sesamol derivative inhibits progression of atherosclerosis.

Authors:  Zhekang Ying; Nisharahmed Kherada; Thomas Kampfrath; Georgeta Mihai; Orlando Simonetti; Rajagopal Desikan; Karuppaiyah Selvendiran; Qinghua Sun; Ouiliana Ziouzenkova; Sampath Parthasarathy; Sanjay Rajagopalan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12-23       Impact factor: 8.311

Review 5.  Nutritional approaches for managing obesity-associated metabolic diseases.

Authors:  Rachel Botchlett; Shih-Lung Woo; Mengyang Liu; Ya Pei; Xin Guo; Honggui Li; Chaodong Wu
Journal:  J Endocrinol       Date:  2017-04-11       Impact factor: 4.286

Review 6.  Skeletal muscle inflammation and insulin resistance in obesity.

Authors:  Huaizhu Wu; Christie M Ballantyne
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 7.  Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment.

Authors:  Patty W Siri-Tarino; Sally Chiu; Nathalie Bergeron; Ronald M Krauss
Journal:  Annu Rev Nutr       Date:  2015       Impact factor: 11.848

8.  Association of the SPT2 chromatin protein domain containing 1 gene rs17579600 polymorphism and serum lipid traits.

Authors:  Tao Guo; Rui-Xing Yin; Yuan Bin; Rong-Jun Nie; Xia Chen; Shang-Ling Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

9.  Nutritional Supplementation with Essential Amino Acids and Phytosterols May Reduce Risk for Metabolic Syndrome and Cardiovascular Disease in Overweight Individuals with Mild Hyperlipidemia.

Authors:  Robert H Coker; Nicolaas E Deutz; Scott Schutzler; Marjorie Beggs; Sharon Miller; Robert R Wolfe; Jeanne Wei
Journal:  J Endocrinol Diabetes Obes       Date:  2015-04-15

Review 10.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.